Search
Vaccines Treatment Options in California
A collection of 332 research studies where Vaccines is the interventional treatment. These studies are located in the California, United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
169 - 180 of 332
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Completed
The objectives of this study were:
* To describe the safety of each dosage of high-dose quadrivalent influenza vaccine (QIV-HD) used in the study during the 28 days following each vaccination, and serious adverse events (including adverse events of special interest throughout the study).
* To describe the antibody response induced by each dosage of QIV-HD used in the study compared with unadjuvanted standard-dose quadrivalent influenza vaccine (QIV-SD) by hemagglutination inhibition (HAI) measu... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
03/24/2022
Locations: Investigational Site Number 8400004, San Diego, California
Conditions: Influenza
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
Completed
The purpose of this study was to evaluate the optimal vaccination schedule for a Quadrivalent Meningococcal Polysaccharide (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (MenACYW Conjugate vaccine) in order to provide an effective protein conjugate quadrivalent meningococcal vaccine in the population with the highest incidence of disease.
Objectives:
* To describe the safety profile of MenACYW Conjugate vaccine administered at 5 different schedules and concomitantly with routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 365 days
Trial Updated:
03/21/2022
Locations: Not set, Fountain Valley, California +1 locations
Conditions: Meningitis, Meningococcal Infection
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
Completed
The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 (MENVEO®) vaccine in children 2 to 9 years of age in the United States (US) and Puerto Rico.
Primary objective:
- To demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y... Read More
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
03/21/2022
Locations: Investigational Site, Anaheim, California +3 locations
Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
Completed
The aim of this study was to evaluate the administration of CYD dengue vaccine serotypes (1, 2, 3 and 4) following a compressed schedule in 3 different populations.
Primary Objectives:
* To describe the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after CYD dengue vaccine Dose 3 in Group 1 (Month \[M\] 13) and Group 2 (M07), irrespective of whether or not Yellow Fever (YF) vaccine has been previously administered.
* To describe the persistenc... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/15/2022
Locations: Not set, Sacramento, California
Conditions: Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
Completed
This was a dose and formulation ranging study to assess the safety and immunogenicity of SP0173 in healthy adolescents, adults, and older adults in the United States (US).
Primary Objective
* To describe the safety profile of each SP0173 investigational formulation.
Observational Objective:
* To describe the immunogenicity of each SP0173 investigational formulation.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
03/15/2022
Locations: Not set, San Diego, California
Conditions: Tetanus, Diphtheria, Pertussis, Whooping Cough
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Completed
The aim of the study was to describe the safety and immunogenicity of a 0.5-mL dose (15 μg hemagglutinin \[HA\] per strain) of Fluzone Quadrivalent vaccine in children 6 to \<36 months of age.
Primary objective:
* To compare the rate of any fever (temperature ≥100.4 degrees Fahrenheit \[38.0 degrees Celsius) following a 0.5-mL dose of Fluzone Quadrivalent vaccine to that following a 0.25-mL dose of Fluzone Quadrivalent vaccine during the 7 days after either vaccination (Dose 1 and Dose 2 combi... Read More
Gender:
ALL
Ages:
Between 6 months and 35 months
Trial Updated:
03/15/2022
Locations: Not set, Downey, California +4 locations
Conditions: Influenza
Novelty, Conformity and Trust in COVID-19 Vaccines
Completed
Despite their established benefits as public measures, vaccines continue to be treated with suspicion by many people, in the US and other parts of the world (Larson et al. 2014; Olive et al. 2018; Lazarus et al. 2020). Since the success of vaccines depends on their high uptake level (Anderson and May, 1985; Fine et al. 2011; Fontanet and Cauchemez, 2020), identifying factors that influence low trust and decision-making in relation to vaccines is essential in order to combat diseases such as the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2022
Locations: SurveyMonkey, San Mateo, California
Conditions: Trust
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Completed
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2021
Locations: VA Loma Linda Healthcare System, Loma Linda, California +4 locations
Conditions: Heart Failure, Myocardial Infarction
Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients
Completed
HIV vaccines may help the immune systems of HIV infected patients better control the virus. The goal of this study is to determine whether patients on anti-HIV medications can stop taking those medications if they receive an HIV vaccine. While taking anti-HIV medications, participants will receive either an HIV vaccine or a placebo. Participants will then stop taking their anti-HIV medications and the study will compare the viral loads of participants who received the vaccine with the viral load... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/04/2021
Locations: UCLA CARE Center CRS, Los Angeles, California +4 locations
Conditions: HIV Infections
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
Completed
Men who have sex with men (MSM) have an increased risk of developing anal human papillomavirus (HPV) infections, which can be a risk factor for anal cancer. HIV-infected women are also at risk of anal cancer. This study will evaluate the effectiveness of the Food and Drug Administration (FDA)-approved quadrivalent HPV vaccine, Gardasil, at preventing anal HPV infection in HIV-infected MSM and HIV-infected women.
Gender:
ALL
Ages:
27 years and above
Trial Updated:
10/29/2021
Locations: UCLA CARE Center CRS, Los Angeles, California +3 locations
Conditions: HIV Infections
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
Completed
The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in fighting pneumococcal infections in this group of children. This study will also look at the protection provided by childhood vaccination against measles, pertussis, and hepatitis B virus.
Pneumococcal infections are the most common AIDS-related infection in HIV-infected ch... Read More
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
10/28/2021
Locations: Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California +4 locations
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
Completed
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other people.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
10/28/2021
Locations: Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California +7 locations
Conditions: HIV Infections, Influenza
169 - 180 of 332